Back to Search Start Over

The financial implications of endovascular aneurysm repair in the cost containment era.

Authors :
Stone DH
Horvath AJ
Goodney PP
Rzucidlo EM
Nolan BW
Walsh DB
Zwolak RM
Powell RJ
Source :
Journal of vascular surgery [J Vasc Surg] 2014 Feb; Vol. 59 (2), pp. 283-290, 290.e1. Date of Electronic Publication: 2013 Oct 17.
Publication Year :
2014

Abstract

Objective: Endovascular aneurysm repair (EVAR) is associated with significant direct device costs. Such costs place EVAR at odds with efforts to constrain healthcare expenditures. This study examines the procedure-associated costs and operating margins associated with EVAR at a tertiary care academic medical center.<br />Methods: All infrarenal EVARs performed from April 2011 to March 2012 were identified (n = 127). Among this cohort, 49 patients met standard commercial instruction for use guidelines, were treated using a single manufacturer device, and billed to Medicare diagnosis-related group (DRG) 238. Of these 49 patients, net technical operating margins (technical revenue minus technical cost) were calculated in conjunction with the hospital finance department. EVAR implant costs were determined for each procedure. DRG 238-associated costs and length of stay were benchmarked against other academic medical centers using University Health System Consortium 2012 data.<br />Results: Among the studied EVAR cohort (age 75, 82% male, mean length of stay, 1.7 days), mean technical costs totaled $31,672. Graft implants accounted for 52% of the allocated technical costs. Institutional overhead was 17% ($5495) of total technical costs. Net mean total technical EVAR-associated operating margins were -$4015 per procedure. Our institutional costs and length of stay, when benchmarked against comparable centers, remained in the lowest quartile nationally using University Health System Consortium costs for DRG 238. Stent graft price did not correlate with total EVAR market share.<br />Conclusions: EVAR is currently associated with significant negative operating margins among Medicare beneficiaries. Currently, device costs account for over 50% of EVAR-associated technical costs and did not impact EVAR market share, reflecting an unawareness of cost differential among surgeons. These data indicate that EVAR must undergo dramatic care delivery redesign for this practice to remain sustainable.<br /> (Copyright © 2014 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.)

Details

Language :
English
ISSN :
1097-6809
Volume :
59
Issue :
2
Database :
MEDLINE
Journal :
Journal of vascular surgery
Publication Type :
Academic Journal
Accession number :
24139984
Full Text :
https://doi.org/10.1016/j.jvs.2013.08.047